Regulatory T-Cells in ALS: Mechanism and Emerging Clinical Evidence
Dr. Uladzislau Tsvirko
26 May 2026
Amyotrophic lateral sclerosis is not a disease of motor neurons alone — neuroinflammation actively drives their loss, and regulatory T-cells are central to it. A review of the mechanism, the link between T-reg function and disease tempo, and the clinical programmes now testing whether restoring T-reg can change the course of ALS.
The immune system's role in ALS
Amyotrophic lateral sclerosis was long viewed as a disease of motor neurons alone. That picture has changed. Over the last two decades, work from groups including Stanley Appel's laboratory has established that neuroinflammation is not a bystander in ALS but an active driver of motor neuron loss. Microglia and infiltrating immune cells shift toward a pro-inflammatory state, and the cells that would normally restrain them — regulatory T-cells — fail to keep pace. This reframing matters, because it identifies the immune system as a target that can be acted on independently of the genetic causes that differ from patient to patient.
What regulatory T-cells do in ALS
Regulatory T-cells (T-reg) are the immune system's brake. In a healthy nervous system they suppress excessive immune activity and help maintain a neuroprotective environment. In ALS, both the number and the suppressive function of T-reg decline, and that decline removes a brake from the neuroinflammatory process. The result is a self-reinforcing cycle: injured motor neurons release signals that activate microglia, microglia amplify inflammation, and weakened T-reg can no longer contain it.
T-reg levels track disease progression
The clinical observation that gives this mechanism weight is that T-reg status correlates with how fast ALS advances. Patients with lower regulatory T-cell numbers and weaker T-reg function tend to progress more rapidly; those who retain stronger T-reg activity tend to progress more slowly. Regulatory T-cells are therefore not only a mechanism but a candidate marker of the disease's inflammatory tempo — which is what makes restoring them a rational therapeutic goal rather than a general anti-inflammatory one.
Restoring T-reg function: the clinical evidence
Two strategies have been tested in humans. The first expands and reinfuses a patient's own regulatory T-cells; early work by Thonhoff and colleagues showed this was feasible and was associated with slower progression in a small number of participants. The second enhances the patient's existing T-reg pharmacologically: Coya Therapeutics' COYA 302 combines low-dose interleukin-2 with CTLA-4-Ig to strengthen endogenous regulatory T-cell function, and its ALSTARS trial is enrolling participants across centres in the United States and Canada. Together these approaches establish regulatory T-cell function as a credible, testable target in ALS.
How this informs cellular therapy
The same biological rationale underlies the regulatory T-cell component of the personalised protocols at BioCells Medical for ALS. Polyclonal T-reg therapy acts across the whole dysregulated neuro-immune environment rather than a single molecule, a multi-target reach suited to a process driven by many pathways at once. It works alongside mesenchymal stem cells and exosomes that address the same inflammatory and trophic pathways from complementary angles. Outcomes from this approach are collected systematically in the clinic's observational ALS registry.
The state of the evidence
The evidence linking regulatory T-cells to ALS is strong at the level of mechanism and consistent at the level of observation, and the field is advancing from biology toward the clinic. What can be said with confidence is that the immune system is part of how ALS progresses, that regulatory T-cells are central to that process, and that restoring their function is one of the most actively studied directions in the field. That is the biological foundation on which immune-focused cell therapy rests.